EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation

The efficacy of EGFR tyrosine kinase inhibitors (TKIs) varies among different EGFR mutations. Here, we directly compared the efficacy of first-line TKIs to chemotherapy for non-small cell lung cancer (NSCLC) patients with the L858R mutation. The progression-free survival (PFS) for patients receiving...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianlin, Yang, Haitang, Jin, Bo, Lou, Yuqing, Zhang, Yanwei, Zhang, Xueyan, Zhong, Hua, Wang, Huiming, Wu, Dan, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095672/
https://www.ncbi.nlm.nih.gov/pubmed/27811976
http://dx.doi.org/10.1038/srep36371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095672/
https://www.ncbi.nlm.nih.gov/pubmed/27811976
http://dx.doi.org/10.1038/srep36371

Ejemplares similares